Skip to main content
. Author manuscript; available in PMC: 2023 Feb 28.
Published in final edited form as: Biomaterials. 2022 Aug 15;288:121729. doi: 10.1016/j.biomaterials.2022.121729

Fig. 6. MEK inhibition does not affect the width of AVM-on-a-chip microvessels.

Fig. 6.

(A) Day 7 distribution of 25% KRAS4AG12V microvessel widths treated with different drugs starting at day 5. (bin size: 10 μm). (B) Average vessel width at day 7 of 25% KRAS4AG12V microvessel treated with DMSO, MEKi, or PI3Ki starting at day 5 show no significant differences. (One-way ANOVA; N = 3; mean ± SD). (C) Day 7 images of KRAS4AG12V microvessels treated with MEKi starting at day 3 (scale bar 500 μm). (D) Average vessel width of 25% KRAS4AG12V micro vasculatures before (day 3) and after (day 7) treatment with MEKi starting day 3. (Paired Student’s t-test; N = 3; mean ± SD). (E) Day 7 vessel width distribution of 25% KRAS4AG12V microvasculatures treated with MEKi starting on day 3 or day 5. (bin size: 10 μm). (F) Average day 7 vessel width of 25% KRAS4AG12V microvasculatures treated with MEKi starting on day 3 or day 5 showing no differences (Unpaired Student’s t-test; N = 3; mean ± SD).